Literature DB >> 28054132

Course of clinical high-risk states for psychosis beyond conversion.

Chantal Michel1, Stephan Ruhrmann2, Benno G Schimmelmann3, Joachim Klosterkötter2, Frauke Schultze-Lutter3.   

Abstract

BACKGROUND: The main focus of research on clinical high-risk states for psychosis (CHR) has been the development of algorithms to predict psychosis. Consequently, other outcomes have been neglected, and little is known about the long-term diagnostic and functional outcome among those not converting to psychosis.
METHODS: In a naturalistic study, incidence, persistence, and remission rates of CHR states according to symptomatic ultra-high risk or cognitive disturbances criteria were investigated in 160 of 246 outpatients of an early detection of psychoses service (21.1% CHR negative and 78.9% CHR positive at baseline) who had not converted to psychosis within follow-up (median 53.7 months, range 13.9-123.7 months).
RESULTS: Remission rate of CHR status was 43.3% of all 194 CHR-positive cases, including converters, or 72.4% if only the 116 non-converters were considered, persistence rate was 27.6%, and new occurrence rate in initially CHR-negative patients was 9.1%. At follow-up, 54.5% of the non-converters met criteria of at least one Axis-I diagnosis, mainly affective and anxiety disorders, and had functional problems. The severity of risk at baseline was not associated with a higher presence of Axis-I diagnosis at follow-up.
CONCLUSIONS: During follow-up, CHR symptoms remitted in one-third of initially CHR-positive patients, while almost 10% met CHR criteria newly in CHR-negative adults presenting at early detection services. The presence of CHR criteria seems to maintain the risk for lower functioning and mental disorders, particularly for affective disorders. Thus, therapeutic efforts targeting CHR patients should also focus on the current mental disorders as well as social and role functions to improve the long-term outcome.

Entities:  

Keywords:  Axis-I diagnosis; Clinical high risk; Non-conversion; Persistence; Remission

Mesh:

Year:  2017        PMID: 28054132     DOI: 10.1007/s00406-016-0764-8

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  40 in total

Review 1.  Risk and protection in prodromal schizophrenia: ethical implications for clinical practice and future research.

Authors:  Nasra Haroun; Laura Dunn; Ansar Haroun; Kristin S Cadenhead
Journal:  Schizophr Bull       Date:  2005-10-05       Impact factor: 9.306

2.  Recovery from an at-risk state: clinical and functional outcomes of putatively prodromal youth who do not develop psychosis.

Authors:  Danielle A Schlosser; Sarah Jacobson; Qiaolin Chen; Catherine A Sugar; Tara A Niendam; Gang Li; Carrie E Bearden; Tyrone D Cannon
Journal:  Schizophr Bull       Date:  2011-08-08       Impact factor: 9.306

Review 3.  The psychosis high-risk state: a comprehensive state-of-the-art review.

Authors:  Paolo Fusar-Poli; Stefan Borgwardt; Andreas Bechdolf; Jean Addington; Anita Riecher-Rössler; Frauke Schultze-Lutter; Matcheri Keshavan; Stephen Wood; Stephan Ruhrmann; Larry J Seidman; Lucia Valmaggia; Tyrone Cannon; Eva Velthorst; Lieuwe De Haan; Barbara Cornblatt; Ilaria Bonoldi; Max Birchwood; Thomas McGlashan; William Carpenter; Patrick McGorry; Joachim Klosterkötter; Philip McGuire; Alison Yung
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

4.  EPA guidance on the early detection of clinical high risk states of psychoses.

Authors:  F Schultze-Lutter; C Michel; S J Schmidt; B G Schimmelmann; N P Maric; R K R Salokangas; A Riecher-Rössler; M van der Gaag; M Nordentoft; A Raballo; A Meneghelli; M Marshall; A Morrison; S Ruhrmann; J Klosterkötter
Journal:  Eur Psychiatry       Date:  2015-02-27       Impact factor: 5.361

5.  Axis I diagnoses and transition to psychosis in clinical high-risk patients EPOS project: prospective follow-up of 245 clinical high-risk outpatients in four countries.

Authors:  Raimo K R Salokangas; Stephan Ruhrmann; Heinrich Graf von Reventlow; Markus Heinimaa; Tanja Svirskis; Tiina From; Sinikka Luutonen; Georg Juckel; Don Linszen; Peter Dingemans; Max Birchwood; Paul Patterson; Frauke Schultze-Lutter; Joachim Klosterkötter
Journal:  Schizophr Res       Date:  2012-03-31       Impact factor: 4.939

Review 6.  Basic symptoms and the prediction of first-episode psychosis.

Authors:  Frauke Schultze-Lutter; Stephan Ruhrmann; Paolo Fusar-Poli; Andreas Bechdolf; Benno G Schimmelmann; Joachim Klosterkötter
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

7.  Symptomatic and functional outcome in youth at ultra-high risk for psychosis: a longitudinal study.

Authors:  Serafín Lemos-Giráldez; Oscar Vallina-Fernández; Purificación Fernández-Iglesias; Guillermo Vallejo-Seco; Eduardo Fonseca-Pedrero; Mercedes Paíno-Piñeiro; Susana Sierra-Baigrie; Pilar García-Pelayo; Clara Pedrejón-Molino; Sandra Alonso-Bada; Ana Gutiérrez-Pérez; Jose Angel Ortega-Ferrández
Journal:  Schizophr Res       Date:  2009-09-27       Impact factor: 4.939

8.  Global assessment of functioning. A modified scale.

Authors:  R C Hall
Journal:  Psychosomatics       Date:  1995 May-Jun       Impact factor: 2.386

9.  Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group.

Authors:  Alison R Yung; Lisa J Phillips; Hok Pan Yuen; Shona M Francey; Colleen A McFarlane; Mats Hallgren; Patrick D McGorry
Journal:  Schizophr Res       Date:  2003-03-01       Impact factor: 4.939

10.  Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis.

Authors:  Paolo Fusar-Poli; Barnaby Nelson; Lucia Valmaggia; Alison R Yung; Philip K McGuire
Journal:  Schizophr Bull       Date:  2012-11-22       Impact factor: 9.306

View more
  22 in total

1.  Prediction Models of Functional Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-Onset Depression: A Multimodal, Multisite Machine Learning Analysis.

Authors:  Nikolaos Koutsouleris; Lana Kambeitz-Ilankovic; Stephan Ruhrmann; Marlene Rosen; Anne Ruef; Dominic B Dwyer; Marco Paolini; Katharine Chisholm; Joseph Kambeitz; Theresa Haidl; André Schmidt; John Gillam; Frauke Schultze-Lutter; Peter Falkai; Maximilian Reiser; Anita Riecher-Rössler; Rachel Upthegrove; Jarmo Hietala; Raimo K R Salokangas; Christos Pantelis; Eva Meisenzahl; Stephen J Wood; Dirk Beque; Paolo Brambilla; Stefan Borgwardt
Journal:  JAMA Psychiatry       Date:  2018-11-01       Impact factor: 21.596

2.  External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample.

Authors:  K Juston Osborne; Vijay A Mittal
Journal:  Psychiatry Res       Date:  2019-06-21       Impact factor: 3.222

Review 3.  Mental Health Services Research Targeting the Clinical High-Risk State for Psychosis: Lessons, Future Directions and Integration with Patient Perspectives.

Authors:  Sarah V McIlwaine; Jai Shah
Journal:  Curr Psychiatry Rep       Date:  2021-02-03       Impact factor: 5.285

4.  Assessment of cognitive impairment in psychosis spectrum disorders through self-reported and interview-based measures.

Authors:  Ana M Sánchez-Torres; Lucía Moreno-Izco; Gustavo J Gil-Berrozpe; Ruth Lorente-Omeñaca; María Zandio; Amalia Zarzuela; Victor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-01       Impact factor: 5.760

5.  The Global Functioning: Social and Role Scales-Further Validation in a Large Sample of Adolescents and Young Adults at Clinical High Risk for Psychosis.

Authors:  Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

6.  Neuropsychological Performance Among Individuals at Clinical High-Risk for Psychosis vs Putatively Low-Risk Peers With Other Psychopathology: A Systematic Review and Meta-Analysis.

Authors:  Zachary B Millman; Caroline Roemer; Teresa Vargas; Jason Schiffman; Vijay A Mittal; James M Gold
Journal:  Schizophr Bull       Date:  2022-09-01       Impact factor: 7.348

7.  Coping with Unusual ExperienceS for 12-18 year olds (CUES+): a transdiagnostic randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associated with unusual experiences in adolescent mental health services: study protocol for a randomised controlled trial.

Authors:  Suzanne Jolley; Sophie Browning; Richard Corrigall; Kristin R Laurens; Colette Hirsch; Karen Bracegirdle; Kimberley Gin; Francesca Muccio; Catherine Stewart; Partha Banerjea; Elizabeth Kuipers; Philippa Garety; Majella Byrne; Juliana Onwumere; Evanthia Achilla; Paul McCrone; Richard Emsley
Journal:  Trials       Date:  2017-12-04       Impact factor: 2.279

Review 8.  Can We Predict Psychosis Outside the Clinical High-Risk State? A Systematic Review of Non-Psychotic Risk Syndromes for Mental Disorders.

Authors:  Tae Young Lee; Junhee Lee; Minah Kim; Eugenie Choe; Jun Soo Kwon
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

Review 9.  Neuroimaging Markers of Resiliency in Youth at Clinical High Risk for Psychosis: A Qualitative Review.

Authors:  Teresa Vargas; Katherine S F Damme; Arielle Ered; Riley Capizzi; Isabelle Frosch; Lauren M Ellman; Vijay A Mittal
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2020-06-10

10.  Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.

Authors:  Gemma Modinos; Anja Richter; Alice Egerton; Ilaria Bonoldi; Matilda Azis; Mathilde Antoniades; Matthijs Bossong; Nicolas Crossley; Jesus Perez; James M Stone; Mattia Veronese; Fernando Zelaya; Anthony A Grace; Oliver D Howes; Paul Allen; Philip McGuire
Journal:  Neuropsychopharmacology       Date:  2021-05-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.